Drug profile

The FDA adverse-event record for Civ Bivalent

13 FDA reports name Civ Bivalent, a lower-volume drug in the CVM extract. Species, reactions, and outcomes follow.

#2228 of 2,679
by report volume (all drugs)
13
adverse-event reports
7.7%
death-coded share
Dog
most-reported species
Verify with FDA CVM →

Corpus placement

According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Civ Bivalent ranks #2210 of 2679 by total reports (13). Death-coded-share rank requires at least 50 reports. National dual: Milbemycin Oxime + Spinosad is #1 of 2679 drugs by total adverse-event reports (149,624) at death-coded-share rank 965 of 1130 drugs with at least 50 reports (2.3%); separately, Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) is #1 highest death-coded share at 97.8% (report rank #821).

149,624
Milbemycin Oxime + Spinosad reports (#1)
97.8%
Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) death share (#1)
#2210
This drug, reports of 2679

Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Civ Bivalent has 13 reports now versus 13 in that prior snapshot: 0 the same number of (0.0%).

Report change
+0
Death-coded reports
+0
Death-coded share
+0.0 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Civ Bivalent changes

Signature read: 13 reports place Civ Bivalent in the lower third of FDA AER volume (#2228 of 2,679).

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
13
Total Reports
1
Deaths Reported
7.7%
Death-coded share of reports

Active Ingredients

Civ Bivalent

Administration Routes

UnknownSubcutaneous

Species Affected

Dog 13

Most Affected Breeds

Retriever - Labrador 4
Terrier - Bull - American Pit 2
Dachshund - Standard Smooth-haired 1
Bulldog 1
Greyhound - Italian 1
Chihuahua 1
Doberman Pinscher 1
Bulldog - French 1
Shepherd Dog - Australian 1

Most Reported Reactions

Vomiting 5
Facial swelling (see also 'Skin') 4
Hives (see also 'Skin') 4
Panting 3
Seizure NOS 3
Lethargy (see also Central nervous system depression in 'Neurological') 2
Vocalisation 2
Anorexia 2
Anaphylaxis 2
Generalised weakness 1
Ataxia 1
Star-gazing 1

Outcome Breakdown

Ongoing
7 (53.8%)
Recovered/Normal
4 (30.8%)
Euthanized
1 (7.7%)
Outcome Unknown
1 (7.7%)

Civ Bivalent: lower report volume in the FDA AER row

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

What to do with this drug

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Civ Bivalent (#2228 of 2,679 by report volume); death-coded 7.7%. PlainBreed drug row · report volume stamp 13 · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →